The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Pancancer survival analysis of cancer hallmark genes
Open accessAbstract
Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study, our aim was to estimate the prognostic effect of the established cancer hallmark genes in multiple distinct cancer types. RNA-seq HTSeq counts and survival data from 26 different tumor types were acquired from the TCGA repository. DESeq was used for normalization. Correlations between gene expression and survival were computed using the Cox proportional hazards regression and by plotting Kaplan–Meier survival plots. The false discovery rate was calculated to correct for multiple hypothesis testing. Signatures based on genes involved in genome instability and invasion reached significance in most individual cancer types. Thyroid and glioblastoma were independent of hallmark genes (61 and 54 genes significant, respectively), while renal clear cell cancer and low grade gliomas harbored the most prognostic changes (403 and 419 genes significant, respectively). The eight genes with the highest significance included BRCA1 (genome instability, HR 4.26, p < 1E−16), RUNX1 (sustaining proliferative signaling, HR 2.96, p = 3.1E−10) and SERPINE1 (inducing angiogenesis, HR 3.36, p = 1.5E−12) in low grade glioma, CDK1 (cell death resistance, HR = 5.67, p = 2.1E−10) in kidney papillary carcinoma, E2F1 (tumor suppressor, HR 0.38, p = 2.4E−05) and EREG (enabling replicative immortality, HR 3.23, p = 2.1E−07) in cervical cancer, FBP1 (deregulation of cellular energetics, HR 0.45, p = 2.8E−07) in kidney renal clear cell carcinoma and MYC (invasion and metastasis, HR 1.81, p = 5.8E−05) in bladder cancer. We observed unexpected heterogeneity and tissue specificity when correlating cancer hallmark genes and survival. These results will help to prioritize future targeted therapy development in different types of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Kaplan–Meier analysis using public breast cancer meta-analysis database11,30 reveals that TNBC patients with higher hypoxia gene signature are associated with worse disease outcomes, including both overall survival (OS) and distant metastasis-free survival (DMFS), compared to those with lower expression of hypoxia gene signature (Fig. 1h).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,438
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Tamoxifen for early breast cancer: an overview of the randomised trials
Abe, O., Bartholomeus, S., & Piccart, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,180
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G. M., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M. A. M., Gelder, M. E. M., Yu, J. X., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,831
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Cited by
Sorted by citations
Items 201–300 of 1,000
Nagasaka, M., Inoue, Y., Yoshida, M., Miyajima, C., Morishita, D., Tokugawa, M., Nakamoto, H., Sugano, M., Ohoka, N., & Hayashi, H. (2022) · FEBS Letters · doi:10.1002/1873-3468.14296 · Cited by 17
Comprehensive Analysis of the Expression and Prognosis for RAD51 Family in Human Breast Cancer
Shi, Y., Shen, M., Xu, M., Tao, M., Chen, K., & Zhu, Q. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s350971 · Cited by 18
la Rosa, M. I. C.-D., Jiménez‐Wences, H., Alarcón‐Millán, J., Romero-López, M. J., Castañón‐Sánchez, C. A., Salmerón-Bárcenas, E. G., & Fernández‐Tilapa, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136993 · Cited by 18
Comprehensive analysis of prognostic significance of cadherin (CDH) gene family in breast cancer
Ku, S., Liu, H.-L., Su, C., Yeh, I., Yen, M., Anuraga, G., Ta, H. D. K., Chiao, C.-C., Xuan, D. T. M., Prayugo, F. B., et al. (2022) · Aging · doi:10.18632/aging.204357 · Cited by 18
CEACAM7 expression contributes to early events of pancreatic cancer
Dhasmana, A., Dhasmana, S., Kotnala, S., Laskar, P., Khan, S., Haque, S., Jaggi, M., Yallapu, M. M., & Chauhan, S. C. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.02.013 · Cited by 18
Anti-HPV16 oncoproteins siRNA therapy for cervical cancer using a novel transdermal peptide PKU12
Deng, Y., Song, Y., Du, Q., Wang, C. C., Hu, L., Sui, Y., Zhang, Y., & Tang, T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1175958 · Cited by 18
An R package for survival-based gene set enrichment analysis
Deng, X., & Thompson, J. A. (2025) · PeerJ · doi:10.7717/peerj.19489 · Cited by 18
Li, M., Zhong, Y., & Wang, M. (2021) · Environmental Toxicology · doi:10.1002/tox.23347 · Cited by 18
Roles of HMGBs in Prognosis and Immunotherapy: A Pan-Cancer Analysis
Lin, T., Zhang, Y., Lin, Z., & Peng, L. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.764245 · Cited by 18
Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity
Mazzu, Y. Z., Liao, Y.-R., Nandakumar, S., Sjöström, M., Jehane, L. E., Ghale, R., Govindarajan, B., Gerke, T. A., Lee, G. M., Luo, J., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13140 · Cited by 18
Wang, L., Feng, X., Jiao, Z., Gan, J., & Meng, Q. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153809 · Cited by 18
Kim, J., & Seok, J. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae325 · Cited by 17
Zhao, W., Nguyen, T. T., Bhagwat, A., Kumar, A., Giotti, B., Kepecs, B., Weirather, J. L., Mahadevan, N. R., Segerstolpe, Å., Dolasia, K., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01053-7 · Cited by 25
FKBP1A upregulation correlates with poor prognosis and increased metastatic potential of HNSCC
Patel, D. M., Dabhi, A. M., Dmello, C., Seervi, M., Sneha, K., Agrawal, P., Sahani, M. H., & Kanojia, D. (2021) · Cell Biology International · doi:10.1002/cbin.11741 · Cited by 17
miR-616-5p Promotes Invasion and Migration of Bladder Cancer via Downregulating NR2C2 Expression
Ren, W., Hu, J., Li, H., Chen, J., Ding, J., Zu, X., & Fan, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.762946 · Cited by 17
TMED2/9/10 Serve as Biomarkers for Poor Prognosis in Head and Neck Squamous Carcinoma
Gao, W., Zhang, Z.-W., Wang, H., Li, X.-D., Peng, W., Guan, H.-Y., Liao, Y., & Liu, A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.895281 · Cited by 17
Potential roles of synaptotagmin family members in cancers: Recent advances and prospects
Suo, H., Xiao, N., & Wang, K. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.968081 · Cited by 17
Yadav, D. K., Sharma, A., Dube, P., Shaikh, S., Vaghasia, H., & Rawal, R. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106036 · Cited by 17
Xing, F., Song, Z., & Cheng, Z. (2022) · Oncology Reports · doi:10.3892/or.2022.8399 · Cited by 17
Yu, W., Kang, C., Zhang, Y., Li, Q., Zhang, Z., Zheng, Y., Liu, X., & Yan, J. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.116125 · Cited by 17
Erk1/2-Dependent HNSCC Cell Susceptibility to Erastin-Induced Ferroptosis
Savic, D., Steinbichler, T. B., Ingruber, J., Negro, G., Aschenbrenner, B., Riechelmann, H., Ganswindt, U., Skvortsov, S., Dudás, J., & Skvortsova, I. (2023) · Cells · doi:10.3390/cells12020336 · Cited by 18
Breast cancer survival analysis agents for clinical decision support
Manzo, G., Pannatier, Y., Duflot, P., Kolh, P. H., Chavez, M., Bleret, V., Calvaresi, D., Jiménez–del–Toro, O. A., Schumacher, M., & Calbimonte, J.-P. (2023) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2023.107373 · Cited by 21
The Role of Apoptotic Genes and Protein-Protein Interactions in Triple-negative Breast Cancer
Adinew, G. M., Messeha, S. S., Taka, E., Ahmed, S. A., & Soliman, K. F. A. (2023) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20379 · Cited by 17
Ibi, H., Takahashi, K., Harada, H., Watabe, T., & Podyma‐Inoue, K. A. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149965 · Cited by 17
Huang, Y., Chen, S., Xiao, L., Qin, W., Li, L., Wang, Y., Ma, L., & Yuan, X. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.744659 · Cited by 16
Meng, X., Wang, X., Zhang, X., Zhang, C., Zhang, Z., Zhang, K., & Wang, S. (2022) · Cells · doi:10.3390/cells11091421 · Cited by 18
VPAC2 Receptor Signaling Promotes Growth and Immunosuppression in Pancreatic Cancer
Passang, T., Wang, S., Zhang, H., Zeng, F., Hsu, P.-C., Wang, W., Li, J.-M., Liu, Y., Ravindranathan, S., Lesinski, G. B., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3628 · Cited by 17
Heyliger, S. O., Soliman, K. F. A., Saulsbury, M. D., & Reams, R. R. (2021) · Biomolecules · doi:10.3390/biom11081193 · Cited by 16
Leal, A. S., Moerland, J. A., Zhang, D., Carapellucci, S., Lockwood, B., Krieger-Burke, T., Aleiwi, B., Ellsworth, E. L., & Liby, K. T. (2021) · Cancers · doi:10.3390/cancers13195004 · Cited by 16
Identification of an mRNA isoform switch for HNRNPA1 in breast cancers
Erdem, M., Ozgul, İ., Dioken, D. N., Gurcuoglu, I., Ergün, S. G., Çetin-Atalay, R., Can, T., & Erson-Bensan, A. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-04007-y · Cited by 17
Comprehensive Analysis of the Prognostic and Immunological Role of PAFAH1B in Pan-Cancer
Yuan, Y., Jiang, X., Tang, L., Wang, J., & Duan, L. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.799497 · Cited by 16
Salnikov, M. Y., Gameiro, S. F., Zeng, P. Y., Barrett, J. W., Nichols, A. C., & Mymryk, J. S. (2022) · mSphere · doi:10.1128/msphere.00317-22 · Cited by 16
Ding, C., Yu, Z., Li, X., Zhu, J., Dai, M., & He, Q. (2023) · Oncology Letters · doi:10.3892/ol.2023.13663 · Cited by 16
Soltan, M. A., Eldeen, M. A., Eid, R. A., Alyamani, N. M., Alqahtani, L. S., Albogami, S. M., Jafri, I., Park, M. N., Alsharif, G., Fayad, E., et al. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1017148 · Cited by 16
Wu, J., Ning, Z., Ding, Y., Wang, Y., Peng, Q., & Fu, L. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad292 · Cited by 17
Prognostic microRNA signature for estimating survival in patients with hepatocellular carcinoma
Sathipati, S. Y., Aimalla, N., Tsai, M., Carter, T., Jeong, S., Wen, Z. H., Shukla, S. K., Sharma, R., & Ho, S. (2023) · Carcinogenesis · doi:10.1093/carcin/bgad062 · Cited by 16
Single-cell and transcriptomic analyses reveal the influence of diabetes on ovarian cancer
Zhao, Z., Wang, Q., Zhao, F., Ma, J., Sui, X., Choe, H. C., Chen, P., Gao, X., & Zhang, L. (2024) · BMC Genomics · doi:10.1186/s12864-023-09893-2 · Cited by 16
Chen, Y., Qiang, Y., Fan, J., Zheng, Q., Yan, L., Fan, G., Song, X., Zhang, N., Lv, Q., Xiong, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45698-x · Cited by 16
Qi, H., Hu, Y., Fan, R., & Deng, L. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3397955 · Cited by 17
Chen, R., Huang, M., Yang, X., Chen, X.-H., Shi, M.-Y., Li, Z.-F., Chen, Z., & Wang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.743050 · Cited by 16
Identification and functional analysis of novel oncogene DDX60L in pancreatic ductal adenocarcinoma
Wu, H., Tian, W., Tai, X., Li, X., Li, Z., Shui, J., Yu, J., Wang, Z., & Zhu, X. (2021) · BMC Genomics · doi:10.1186/s12864-021-08137-5 · Cited by 16
Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis
Hendrikson, J., Liu, Y., Ng, W. H., Lee, J. Y., Lim, A. H., Loh, J. W., Ng, C. C. Y., Ong, W. S., Tan, J. W., Tan, Q. X., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100526 · Cited by 16
Pan-Cancer Analysis Predicts FOXS1 as a Key Target in Prognosis and Tumor Immunotherapy
Liu, Y., Tu, M., & Wang, L. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s354195 · Cited by 16
Zhou, J., Tang, J., Zuo, Y., Wan, P., Zhang, D., & Shao, W. (2025) · IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings - IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings · doi:10.1109/cvpr52734.2025.00971 · Cited by 21
Lazo, J. S., Sharlow, E. R., Cornelison, R., Hart, D. J., Llaneza, D. C., Mendelson, A. J., Rastelli, E. J., Tasker, N. R., Landen, C. N., & Wipf, P. (2021) · Biomolecules · doi:10.3390/biom11070969 · Cited by 15
Rahimi, N., Ho, R. X.-Y., Chandler, K. B., Cena, K. O. C. D. L., Amraei, R., Mitchel, A. J., Engblom, N., & Costello, C. E. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00757-z · Cited by 15
Zhang, H., Zhang, X., Xu, W., & Wang, J. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.810864 · Cited by 15
Cyclin genes as potential novel prognostic biomarkers and therapeutic targets in breast cancer
Liu, N.-Q., Cao, W., Wang, X., Chen, J., & Nie, J. (2022) · Oncology Letters · doi:10.3892/ol.2022.13494 · Cited by 18
Zhou, L., Li, H., Zhang, D., Chen, L., Dong, H., Yuan, Y., & Wang, T. (2022) · Oncology Reports · doi:10.3892/or.2022.8419 · Cited by 15
Duan, Y., Du, Y., Gu, Z., Zheng, X., & Wang, C. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1036287 · Cited by 15
Cao, B., Zhao, R., Li, H., Xu, X., Gao, J., Chen, L., & Wei, B. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.75106 · Cited by 15
Donovan, J., Deng, Z., Bian, F., Shukla, S., Gomez‐Arroyo, J. G., Shi, D., Kalinichenko, V. V., & Kalin, T. V. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1112859 · Cited by 16
Das, A., Prajapati, A., Karna, A., Sharma, H. K., Uppal, S., Lather, V., Pandita, D., & Agarwal, P. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110443 · Cited by 15
Gündeşli, H., Kori, M., & Arğa, K. Y. (2023) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2023.0053 · Cited by 15
Wang, Q., Chen, F., Yang, N., Xu, L., Yu, X., Wu, M., & Zhou, Y. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00249.2023 · Cited by 15
MORG1 limits mTORC1 signaling by inhibiting Rag GTPases
Abudu, Y. P., Kournoutis, A., Brenne, H. B., Lamark, T., & Johansen, T. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.11.023 · Cited by 17
Atkins, D. J., Rosas, J. M., Månsson, L. K., Shahverdi, N., Dey, S. S., & Pitenis, A. A. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c01079 · Cited by 15
Lee, H. J., Kwak, Y., Na, Y. S., Kim, H.-J., Park, M. R., Jo, J. Y., Kim, J. Y., Cho, S., & Kim, P. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100843 · Cited by 17
Lin, H., Wu, H., Chen, S., Hou, M., Lin, C., & Chu, P. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112431 · Cited by 15
Luque, M., Sanz-Álvarez, M., Santamaría, A., Zazo, S., Cristóbal, I., de la Fuente, L., Mínguez, P., Eroles, P., Rovira, A., Albanell, J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413297 · Cited by 17
Bonnet‐Magnaval, F., Diallo, L. H., Brunchault, V., Laugero, N., Morfoisse, F., David, F., Roussel, É., Nougué, M., Zamora, A., Marchaud, E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010215 · Cited by 15
Yu, Y., Sun, Y., Li, Z., Jiang, L., & Tian, D. (2023) · BMC Bioinformatics · doi:10.1186/s12859-023-05165-8 · Cited by 15
MMOSurv: meta-learning for few-shot survival analysis with multi-omics data
Wen, G., & Li, L. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae684 · Cited by 14
Wu, J., Luo, M., Chen, Z., Li, L., & Huang, X. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.737656 · Cited by 14
Huang, Y., Huang, S., Ma, L., Wang, Y., Wang, X., Xiao, L., Qin, W., Li, L., & Yuan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.723293 · Cited by 14
Yousefi, H., Fong, J. T., & Alahari, S. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.777824 · Cited by 14
Chou, H.-C., Cheng, C.-M., Yang, C., Lin, T., Liu, Y., Tan, T., & Chen, Y. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00826-x · Cited by 18
Luo, W., Wu, S., Zhang, F., Chen, X., Ma, Y., & Mo, Y. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154111 · Cited by 14
Gucht, M. V. D., Dufait, I., Kerkhove, L., Corbet, C., de Mey, S., Jiang, H., Ka, L. L., Gevaert, T., Féron, O., & Ridder, M. D. (2022) · Cancers · doi:10.3390/cancers14205060 · Cited by 15
Eid, R. A., Eldeen, M. A., Soltan, M. A., Al-Shraim, M. M., Aldehri, M., Alqahtani, L. S., Alsharif, G., Albogami, S. M., Jafri, I., Fayad, E., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1008502 · Cited by 14
Zhou, Z., Zhou, Q., Zhao, J., Hou, X., Yan, J., Sun, X., Yang, Z., Ma, J., Zhang, F., Zhan, L., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87867 · Cited by 15
Cancer Biology and Therapeutics: Navigating Recent Advances and Charting Future Directions
Cleanclay, W. D., Zakari, S., Adigun, T. O., Ayeni, T. O., Nnaji, P. C., Amuji, D. N., Blessing, A., Adebosoye, A., Gbadebo, M., Agbetuyi-Tayo, P., et al. (2023) · Tropical Journal of Natural Product Research · doi:10.26538/tjnpr/v7i12.4 · Cited by 17
Eldeen, M. A., Mamdouh, F., Abdulsahib, W. K., Eid, R. A., Alhanshani, A. A., Shati, A. A., Alqahtani, Y. A., Alshehri, M. A., Zaki, M. S. A., Soltan, M. A., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17020152 · Cited by 14
miR-497 Target Gene Regulatory Network in Angiosarcoma
Benton, A., Terwilliger, E., Moriarty, N. M., Liu, B., Murphy, A., Maluvac, H., Shu, M., Gartenhaus, L. E., Janson, N. D., Pfeffer, C. M., et al. (2024) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-1075 · Cited by 14
Selective metabolic regulations by p53 mutant variants in pancreatic cancer
Caporali, S., Butera, A., Ruzza, A., Zampieri, C., Bantulà, M., Scharsich, S., Ückert, A., Celardo, I., Kouzel, I. U., Leanza, L., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03232-3 · Cited by 14
Reciprocal interplay between asporin and decorin: Implications in gastric cancer prognosis
Basak, D., Jamal, Z., Ghosh, A., Mondal, P. K., Talukdar, P. D., Ghosh, S., Roy, B. G., Ghosh, R., Halder, A., Chowdhury, A., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255915 · Cited by 14
Zhu, Y., Wang, X., Xu, Y., Chen, L., Ding, P., Chen, J., & Hu, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.736725 · Cited by 14
Huang, Y., Xie, B., Cao, M., Lu, H., Wu, X., Hao, Q., & Zhou, X. Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.730538 · Cited by 14
Overexpression of IRF3 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma
Wu, J., Leng, X., Pan, Z., Xu, L., & Zhang, H. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s328225 · Cited by 14
Fan, Y., Xie, G., Wang, Z., Wang, Y., Wang, Y., Zheng, H. Y., & Zhong, X. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06463-6 · Cited by 14
Li, F., Wang, M., Li, X., Long, Y., Chen, K., Wang, X., Zhong, M., Cheng, W., Tian, X., Wang, P., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.01.011 · Cited by 14
Gao, Y., Yuan, L., Zeng, J., Li, F.-Y., Li, X., Tan, F., Liu, X.-S., Wan, H.-B., Kui, X., Liu, X., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03503-7 · Cited by 13
An HLA-G/SPAG9/STAT3 axis promotes brain metastases
Bassey-Archibong, B. I., Chokshi, C., Aghaei, N., Kieliszek, A., Tatari, N., McKenna, D., Singh, M., Subapanditha, M., Parmar, A., Mobilio, D., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205247120 · Cited by 14
SLC35B4 Stabilizes c-MYC Protein by O-GlcNAcylation in HCC
Jiang, T., Yang, J., Yang, H.-H., Chen, W., Ji, K., Xu, Y., & Yu, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.851089 · Cited by 14
Zhu, R., Tu, Y., Chang, J., Xu, H., Li, J. C., Liu, W., Do, A.-D., Zhang, Y., Wang, J., & Li, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.691199 · Cited by 13
Mondal, A., Paul, D., Dastidar, S. G., Saha, T., & Goswami, A. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-19299-x · Cited by 13
The Dual Function of RhoGDI2 in Immunity and Cancer
Tripathi, M., Colige, A., & Deroanne, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044015 · Cited by 12
RETRACTED ARTICLE: Palmitoyl transferases act as novel drug targets for pancreatic cancer
Lin, Z., Lv, Z., Liu, X., & Huang, K. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04098-3 · Cited by 13
RetractedMurugesan, D., Kannan, B., Girija, A. S. S., Jayaseelan, V. P., & Arumugam, P. (2024) · Journal of Stomatology Oral and Maxillofacial Surgery · doi:10.1016/j.jormas.2024.101811 · Cited by 13
Jeong, J., Kim, D. K., Park, J., Park, D. J., Lee, H., Yang, H., Kong, S., & Jung, K. (2021) · Immune Network · doi:10.4110/in.2021.21.e31 · Cited by 14
The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells
Yu, R.-N., Kim, J. Y., Chang, H.-S., Kim, M., Do, Y. T., Vo, T., Choi, E., Ha, E., Seo, J., & Shin, S.-J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910817 · Cited by 11
Karan, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.727583 · Cited by 13
Tarek, M., Yahia, A., Elnakib, M., & ElHefnawi, M. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104986 · Cited by 14
Rho GTPase gene expression and breast cancer risk: a Mendelian randomization analysis
Kazmi, N., Robinson, T., Zheng, J., Kar, S., Martin, R. M., & Ridley, A. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-05549-5 · Cited by 13
SNRPD1/E/F/G Serve as Potential Prognostic Biomarkers in Lung Adenocarcinoma
Liu, G., Li, F., Chen, M., Luo, Y., Dai, Y., & Hou, P. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.813285 · Cited by 13
The Prognostic Value and Immune Infiltration of USP10 in Pan-Cancer: A Potential Therapeutic Target
Gao, D., Zhang, Z., Rui, X., He, Z., Li, F., Hu, Y., Chen, H., Lu, J., Cao, X., Liu, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.829705 · Cited by 13
TIMP2 is associated with prognosis and immune infiltrates of gastric and colon cancer
Jian, F., Yanhong, J., Limeng, W., Guoping, N., Yiqing, T., Hao, L., & Pan, Z. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109008 · Cited by 13
Sun, K., Hong, J.-J., Chen, D., Luo, Z., & Li, J.-Z. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02423-6 · Cited by 13
Jin, R., Zeng, C., & Chen, Y. (2022) · PubMed · doi:10.14670/hh-18-526 · Cited by 13
miR766-3p and miR124-3p Dictate Drug Resistance and Clinical Outcome in HNSCC
Shibata, T., Cao, D., Dar, T. B., Ahmed, F., Bhat, S. A., Veiras, L. C., Bernstein, E. A., Khan, A. A., Chaum, M., Shiao, S. L., et al. (2022) · Cancers · doi:10.3390/cancers14215273 · Cited by 13
Metadata
- Authors
- Nagy, Á., Munkácsy, G., & Győrffy, B.
- Affiliations
- Semmelweis University (HU)
- Corresponding author
- Győrffy, Balázs
- Venue
- Scientific Reports
- Published
- 2021-03-15
- Volume
- 11
- Issue
- 1
- Pages
- 6047-6047
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC7961001
- OpenAlex
- W3139511935
- Cited by
- 1,381
- References
- 40
- Citations by year
- 2026: 38 · 2025: 84 · 2024: 145 · 2023: 504 · 2022: 311 · 2021: 298
- FWCI
- 101.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Semmelweis Egyetem
- Innovációs és Technológiai Minisztérium (ÚNKP-19-3, 2018-2.1.17-TET-KR-00001)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- prognostic gene signature, survival analysis, genomic instability, invasion and metastasis, replicative immortality, cell death resistance, angiogenesis, tumor suppressor, BRCA1, RUNX1, SERPINE1, CDK1, E2F1, epiregulin, c-Myc, clear cell renal cell carcinoma, low-grade glioma, cervical cancer, bladder cancer, thyroid cancer, glioblastoma, tissue specificity, targeted therapy
- MeSH terms
- RNA-Seq, Humans, Neoplasms, Biomarkers, Tumor, Survival Rate, Disease-Free Survival, Databases, Nucleic Acid, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
